Back to top
more

Hepion Pharmaceuticals (HEPA)

(Delayed Data from NSDQ)

$1.12 USD

1.12
43,634

-0.02 (-1.76%)

Updated May 24, 2024 03:41 PM ET

After-Market: $1.11 -0.01 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for HEPA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Hepion Pharmaceuticals, Inc. [HEPA]

Reports for Purchase

Showing records 21 - 40 ( 52 total )

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

06/03/2020

Company Report

Pages: 8

Five Reasons to Meet the Team in June with Phase 2a NASH Data in YE20

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

05/27/2020

Company Report

Pages: 18

Competing in the NASH dash -Initiation of coverage

Provider: Edison Investment Research Limited

Analyst: CALLOWAY N

Price: .00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

05/22/2020

Industry Report

Pages: 4

Healthcare- Three Must Dial-In Calls Next Week:

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

05/21/2020

Industry Report

Pages: 4

Three Must Dial-In Calls Next Week: NASH, Omega-3s, and COVID-19 - MS

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

05/20/2020

Company Report

Pages: 8

CRV431 Soon to Enter the Ph2a Arena

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

05/20/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

04/28/2020

Industry Report

Pages: 3

Healthcare Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

04/24/2020

Industry Report

Pages: 3

Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm ET

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

04/20/2020

Industry Report

Pages: 3

Dial in Today to Part 1 of Our 4-Part NASH COVID-19 Call Series

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

04/16/2020

Industry Report

Pages: 4

Do Not Miss Part 1 on Monday of Our 4-Part NASH COVID-19 Call Series

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

04/02/2020

Industry Report

Pages: 10

Dial in to Part 2 of Our COVID-19 Drug Developer Call Series Today at 12PM

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

04/01/2020

Daily Note

Pages: 10

Healthcare Dial in to Part 1 of Our COVID-19 Drug Developer Call Series Today at 12PM

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

03/30/2020

Industry Report

Pages: 10

Healthcare - Dial in to Parts 1-2 of Our COVID-19 Drug Developer Series on Apr. 1 - Apr. 2

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

03/24/2020

Industry Report

Pages: 10

Meet Our COVID-19 Drug Developers Call Series

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

03/20/2020

Industry Report

Pages: 6

Coronavirus Note, Vol. 5: COVID-19 in Co-Morbidities, Chloroquine, and More

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

02/28/2020

Industry Report

Pages: 9

NASH/CVD/Renal Companies to See and Why at Our 32nd Conference?

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

02/21/2020

Industry Report

Pages: 3

Do Not Forget to Dial-in to Our NASH Call Today with Dr. Arun Sanyal at 1PM

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

02/18/2020

Industry Report

Pages: 3

Our NASH Expert Call with Dr. Arun Sanyal Moved to Friday, Feb. 21, at 1PM ET

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

02/18/2020

Industry Report

Pages: 3

Do Not Forget to Dial-in to Our Call Today with Dr. Arun Sanyal at 12pm

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Hepion Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

02/14/2020

Industry Report

Pages: 10

Healthcare - Can''t Miss Takeaways from our NASH Fibrosis Expert Call with Dr. Scott Friedman

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party